|
1
|
Wu X, Piper-Hunter MG, Crawford M, Nuovo
GJ, Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNAs in the
pathogenesis of lung cancer. J Thorac Oncol. 4:1028–1034. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: recent
advances and future directions. Oncologist. 15:5–13. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Curran WJ Jr: Treatment of locally
advanced non-small cell lung cancer: what we have and have not
learned over the past decade. Semin Oncol. 32:S2–S5. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar
|
|
5
|
Duffy MJ, McKiernan E, O’Donovan N and
McGowan PM: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saftig P and Reissb K: The ‘A Disintegrin
and metalloproteases’ ADAM10 and ADAM17: novel drug targets with
therapeutic potential? Eur J Cell Biol. 90:527–535. 2011.
|
|
7
|
Shintani Y, Higashiyama S, Ohta M, et al:
Overexpression of ADAM9 in non-small cell lung cancer. Cancer Res.
64:4190–4196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsai WC, Hsu PW, Lai TC, et al:
MicroRNA-122, a tumor suppressor microRNA that regulates
intrahepatic metastasis of hepatocellular carcinoma. Hepatology.
49:1571–1582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gaida MM, Haag N, Günther F, Tschaharganeh
DF, Schirmacher P, Friess H, Giese NA, Schmidt J and Wente MN:
Expression of A disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
10
|
Crawford HC, Dempsey PJ, Brown G, Adam L
and Moss ML: ADAM10 as a therapeutic target for cancer and
inflammation. Curr Pharm Des. 15:2288–2299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW
and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10)
expression in oral squamous cell carcinoma. Cancer Lett. 245:33–43.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fogel M, Gutwein P, Mechtersheimer S, et
al: L1 expression as a predictor of progression and survival in
patients with uterine and ovarian carcinomas. Lancet. 362:869–875.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee SB, Schramme A, Doberstein K, et al:
ADAM10 is upregulated in melanoma metastasis compared with primary
melanoma. J Invest Dermatol. 130:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou BB, Peyton M, He B, et al: Targeting
ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in
non-small cell lung cancer. Cancer Cell. 10:39–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galluzzo P and Bochetta M: Notch signaling
in lung cancer. Expert Rev Anticancer Ther. 11:533–540. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
López-Malpartida AV, Ludeña MD, Varela G
and García Pichel J: Differential ErbB receptor expression and
intracellular signaling activity in lung adenocarcinomas and
squamous cell carcinomas. Lung Cancer. 65:25–33. 2009.PubMed/NCBI
|
|
17
|
Pelosi G, Scarpa A, Puppa G, et al:
Alteration of the E-cadherin/β-catenin cell adhesion system is
common in pulmonary neuroendocrine tumors and is an independent
predictor of lymph node metastasis in atypical carcinoids. Cancer.
103:1154–1164. 2005.
|
|
18
|
Lai EC: Notch signaling: control of cell
communication and cell fate. Development. 131:965–973. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Y, Ahn YH, Gibbons DL, et al: The
Notch ligand Jagged2 promotes lung adenocarcinoma metastasis
through a miR-200-dependent pathway in mice. J Clin Invest.
121:1373–1385. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Konishi J, Kawaguchi KS, Vo H, Haruki N,
Gonzalez A, Carbone DP and Dang TP: γ-secretase inhibitor prevents
Notch3 activation and reduces proliferation in human lung cancers.
Cancer Res. 67:8051–8057. 2007.
|
|
21
|
Chen Y, Li D, Liu H, et al: Notch-1
signaling facilitates survivin expression in human non-small cell
lung cancer cells. Cancer Biol Ther. 11:14–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ji X, Wang Z, Geamanu A, Sarkar FH and
Gupta SV: Inhibition of cell growth and induction of apoptosis in
non-small cell lung cancer cells by delta-tocotrienol is associated
with Notch-1 down-regulation. J Cell Biochem. 112:2773–2783. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Westhoff B, Colaluca IN, D’Ario G, et al:
Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci
USA. 106:22293–22298. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Donnem T, Andersen S, Al-Shibli K, Al-Saad
S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and
receptors in nonsmall cell lung cancer. Cancer. 116:5676–5685.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hartmann D, de Strooper B, Serneels L, et
al: The disintegrin/metalloprotease ADAM 10 is essential for Notch
signalling but not for α-secretase activity in fibroblasts. Hum Mol
Genet. 11:2615–2624. 2002.PubMed/NCBI
|
|
26
|
Miele L: Notch signaling. Clin Cancer Res.
12:1074–1079. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gavert N, Conacci-Sorrell M, Gast D,
Schneider A, Altevogt P, Brabletz T and Ben-Ze’ev A: L1, a novel
target of β-catenin signaling, transforms cells and is expressed at
the invasive front of colon cancers. J Cell Biol. 168:633–642.
2005.
|
|
28
|
Xu Q, Liu X, Chen W and Zhang Z:
Inhibiting adenoid cystic carcinoma cells growth and metastasis by
blocking the expression of ADAM 10 using RNA interference. J Transl
Med. 8:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grabher C, von Boehmer H and Look AT:
Notch 1 activation in the molecular pathogenesis of T-cell acute
lymphoblastic leukaemia. Nat Rev Cancer. 6:347–359. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pang RT, Leung CO, Ye TM, et al:
MicroRNA-34a suppresses invasion through downregulation of Notch1
and Jagged1 in cervical carcinoma and choriocarcinoma cells.
Carcinogenesis. 31:1037–1044. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nam DH, Jeon HM, Kim S, et al: Activation
of Notch signaling in a xenograft model of brain metastasis. Clin
Cancer Res. 14:4059–4066. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Z, Banerjee S, Li Y, et al:
Down-regulation of Notch-1 inhibits invasion by inactivation of
nuclear factor-κB, vascular endothelial growth factor, and matrix
metalloproteinase-9 in pancreatic cancer. Cancer Res. 66:2778–2784.
2006.
|
|
33
|
Sullivan JP, Spinola M, Dodge M, et al:
Aldehyde dehydrogenase activity selects for lung adenocarcinoma
stem cells dependent on notch signaling. Cancer Res. 70:9937–9948.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
van Tetering G, van Diest P, Verlaan I,
van der Wall E, Kopan R and Vooijs M: Metalloprotease ADAM10 is
required for Notch1 site 2 cleavage. J Biol Chem. 284:31018–31027.
2009.PubMed/NCBI
|
|
35
|
Brou C, Logeat F, Gupta N, et al: A novel
proteolytic cleavage involved in Notch signaling: the role of the
disintegrin-metalloprotease TACE. Mol Cell. 5:207–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bozkulak EC and Weinmaster G: Selective
use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol
Cell Biol. 29:5679–5695. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie M, Zhang L, He CS, et al: Activation
of Notch-1 enhances epithelial-mesenchymal transition in
gefitinib-acquired resistant lung cancer cells. J Cell Biochem.
113:1501–1513. 2012.PubMed/NCBI
|
|
38
|
McGowan PM, Simedrea C, Ribot EJ, et al:
Notch1 inhibition alters the CD44hi/CD24lo population and reduces
the formation of brain metastases from breast cancer. Mol Cancer
Res. 9:834–844. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bolós V, Blanco M, Medina V, Aparicio G,
Díaz-Prado S and Grande E: Notch signaling in cancer stem cells.
Clin Transl Oncol. 11:11–19. 2009.
|
|
40
|
Pannuti A, Foreman K, Rizzo P, Osipo C,
Golde T, Osborne B and Miele L: Targeting Notch to target cancer
stem cells. Clin Cancer Res. 16:3141–3152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Barten DM, Meredith JE Jr, Zaczek R,
Houston JG and Albright CF: Gamma-secretase inhibitors for
Alzheimer’s disease: balancing efficacy and toxicity. Drugs R D.
7:87–97. 2006.
|
